Valeant Pharmaceuticals Announces Approval of Retin-A Micro® Microsphere 0.08%; Techne Announces Partnership Agreement With Fisher Scientific Print E-mail
By Mary Davila   
Friday, 31 January 2014 20:09
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 31, 2014.

Valeant Pharmaceuticals International (NYSE: VRX)
announced it has received approval from the Food and Drug Administration (FDA) for its Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) Gel microsphere 0.08% for the topical treatment of acne vulgaris.

"We are very pleased that the FDA has approved our new strength of Retin-A Micro® as this gives health care providers and patients a new option for the topical treatment of acne vulgaris," stated J. Michael Pearson, chairman and chief executive officer. "This new strength will provide physicians and patients another effective treatment and should be a welcome alternative to current strengths. We look forward to launching 0.08% Retin-A Micro® in the near future."


======================


Techne Corporation (NASDAQ: TECH)
today announced  a three year agreement to distribute Techne's R&D Systems, Tocris, and Boston Biochem brand catalog products through the Fisher Scientific customer channel in the United States and Canada.   Fisher Scientific, the premier customer channel brand within Thermo Fisher Scientific, has a leading position in the life sciences market and represents broad customer reach and a proven record of customer service and support.
As a preferred supplier, Techne will be able to leverage the commercial strength of the Fisher Scientific channel through its large sales force and highly trained life science application specialists.  In addition, Techne will be well positioned to take advantage of the many Fisher Scientific marketing programs including advanced e-commerce solutions and occupy a prominent position in the Fisher Scientific catalog.

Techne will continue to market and provide technical support to their existing customers as well as all new customers introduced through the extensive Fisher Scientific channel.  The partnership will expose Techne's products to a greater number of academic, governmental and industrial customers, including those in the pharmaceutical, biotechnology and CRO segments.  It will also expand the range of high-quality proteins, antibodies and immunoassays offered under the Fisher Scientific brand.


Also Friday:


Alcobra Ltd. (Nasdaq:ADHD)
, an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at the BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City on February 10-11, 2014.

Alternative Energy Partners (OTCBB: AEGY) (OTCQB: AEGY)
, known as PharmaJanes, is pleased to announce that PharmaJanes.com, the e-commerce servicing platform, is now open for new patient enrollment. PharmaJanes will first begin servicing parts of metropolitan Southern California, and thereafter will expand throughout California in phases.

AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG)
today announced that the United States Patent and Trademark Office (USPTO) has issued a new U.S. patent to AMAG for ferumoxytol, U.S. Patent No. 8,591,864, Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents, expiring in March 2020.

CollabRx, Inc. (Nasdaq:CLRX)
, a data analytics company focused on genomics, today announced that it will hold an investor conference call on February 11, 2014 to discuss the Company's financial results for the third quarter of fiscal 2014 and to provide an update about the business in the current fiscal year.

Eli Lilly and Company (NYSE: LLY)
has provided the following statement regarding a lawsuit filed by Sanofi in the United States District Court for the District of Delaware alleging patent infringement with respect to LY2963016, a new insulin glargine product for which Lilly is currently seeking approval from the U.S. Food and Drug Administration (FDA).

Oxford Immunotec Global PLC (Nasdaq:OXFD)
announced today that its CEO, Dr. Peter Wrighton-Smith has been named the UK BioIndustry Association Entrepreneur of the Year.

OxySure Systems, Inc. (OTCQB: OXYS)
, the medical device innovator of life-saving easy-to-use emergency oxygen solutions with its "oxygen from powder" technology today announced that the Company will host a conference call to update shareholders and other interested parties on Tuesday, February 4, 2014 at 10:30 a.m. Central Time - 11:30 a.m. Eastern Time.

Physicians Healthcare Management Group, Inc. (OTC:PHYH)
announced today that it has decided to pursue a new business model to focus its management capabilities to industries beyond healthcare.

Prosensa Holding N.V. (NASDAQ: RNA)
announced today that it is schedule to participate at the following investor conferences in  February.

Q4 Systems Corporation (OTCQB:QFOR)
, is pleased to announce that they will be implementing their comprehensive QHIX Health Exchange Platform for The Hatcher Agency, Arkansas' largest insurance group.

SK3 Group, Inc's (OTC Pink: SKTO)
subsidiary Medical Greens is pleased to announce that it has officially launched its Janes Card™ benefits and payment card.

Sigma-Aldrich Corporation (NASDAQ: SIAL)
, a leading Life Science and High Technology company, announced they will be presenting at the following investor conferences in February:  Leerink Swann Global Healthcare Conference 2014 on Thursday, February 13, 2014 in New York City, presenting at 1:50 PM (Eastern);  2014 Citi Global Healthcare Conference on Tuesday, February 25, 2014 in New York City, presenting at 1:00 PM (Eastern).

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved HETLIOZ™ (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).  HETLIOZ™ is the first FDA approved medication for Non-24.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter